ES2139002T3 - Terapia medicamentosa citotoxica. - Google Patents
Terapia medicamentosa citotoxica.Info
- Publication number
- ES2139002T3 ES2139002T3 ES93901820T ES93901820T ES2139002T3 ES 2139002 T3 ES2139002 T3 ES 2139002T3 ES 93901820 T ES93901820 T ES 93901820T ES 93901820 T ES93901820 T ES 93901820T ES 2139002 T3 ES2139002 T3 ES 2139002T3
- Authority
- ES
- Spain
- Prior art keywords
- cytotoxic agent
- drug therapy
- cytotoxic drug
- tumorous
- inactivation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6895—Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3007—Carcino-embryonic Antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/819—Multifunctional antigen or antibody
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Nanotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Abstract
UN COMPONENTE COMPRENDE UNA PARTE DE OBJETIVO ESPECIFICO DE CELULAS, TALES COMO UN ANTICUERPO ESPECIFICO PARA ANTIGENOS DE CELULAS TUMOROSAS, Y UNA PARTE DE INACTIVACION, TAL COMO UNA ENZIMA, CAPAZ DE CONVERTIR UNA SUSTANCIA QUE EN SU ESTADO NATIVO ES CAPAZ DE INHIBIR LOS EFECTOS DE UN AGENTE CITOTOXICO EN UNA SUSTANCIA QUE TENGA MENOS EFECTO CONTRA DICHO AGENTE CITOTOXICO. LA ACCION PROLONGADA DE UN AGENTE CITOTOXICO EN LUGARES TUMOROSOS ES POR TANTO POSIBLE A LA VEZ QUE SE PROTEGEN LOS TEJIDOS NORMALES DE LOS EFECTOS DEL AGENTE CITOTOXICO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB929200417A GB9200417D0 (en) | 1992-01-09 | 1992-01-09 | Cytotoxic drug therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2139002T3 true ES2139002T3 (es) | 2000-02-01 |
Family
ID=10708338
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES93901820T Expired - Lifetime ES2139002T3 (es) | 1992-01-09 | 1993-01-11 | Terapia medicamentosa citotoxica. |
Country Status (8)
Country | Link |
---|---|
US (3) | US5658568A (es) |
EP (1) | EP0620741B1 (es) |
JP (2) | JP3592711B2 (es) |
CA (1) | CA2124218C (es) |
DE (1) | DE69326539T2 (es) |
ES (1) | ES2139002T3 (es) |
GB (2) | GB9200417D0 (es) |
WO (1) | WO1993013805A1 (es) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5776093A (en) | 1985-07-05 | 1998-07-07 | Immunomedics, Inc. | Method for imaging and treating organs and tissues |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
DE4233152A1 (de) | 1992-10-02 | 1994-04-07 | Behringwerke Ag | Antikörper-Enzym-Konjugate zur Prodrug-Aktivierung |
GB9524942D0 (en) * | 1995-12-06 | 1996-02-07 | Aepact Ltd | Drug therapy |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
JP3266276B2 (ja) * | 1996-07-25 | 2002-03-18 | ゲーエスエフ―フォルシュングスツェントゥルム・フューア・ウムヴェルト・ウント・ゲズントハイト・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 二重特異性抗体断片の簡易化した製造 |
GB9712370D0 (en) | 1997-06-14 | 1997-08-13 | Aepact Ltd | Therapeutic systems |
WO1999018792A1 (en) * | 1997-10-10 | 1999-04-22 | Johns Hopkins University | Gene delivery compositions and methods |
US6043367A (en) * | 1998-09-30 | 2000-03-28 | Roffler; Steve | Proactive antitumor compounds |
EP2267026A1 (en) * | 2000-04-12 | 2010-12-29 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20030147874A1 (en) * | 2000-12-14 | 2003-08-07 | Volker Schellenberger | Targeted enzyme prodrug therapy |
US20030049689A1 (en) * | 2000-12-14 | 2003-03-13 | Cynthia Edwards | Multifunctional polypeptides |
US20080248544A1 (en) * | 2000-12-14 | 2008-10-09 | Murray Christopher J | Methods And Compositions For Grafting Functional Loops Into A Protein |
US7445802B2 (en) * | 2000-12-26 | 2008-11-04 | Yeda Research And Development Co. Ltd | Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases |
CA2446739A1 (en) * | 2001-05-25 | 2002-12-05 | Human Genome Sciences, Inc. | Chemokine beta-1 fusion proteins |
EP2009019A1 (en) * | 2001-06-05 | 2008-12-31 | Altor BioScience Corporation | P53 binding T cell receptor molecules and uses thereof |
PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
DE10205520A1 (de) * | 2002-02-08 | 2003-08-14 | Aventis Behring Gmbh | Inhibitorischer, monoklonaler Antikörper gegen die den Blutgerinnungsfaktor VII aktivierende Protease |
ES2358730T3 (es) | 2002-07-15 | 2011-05-13 | Board Of Regents, The University Of Texas System | Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer. |
DE10256042B4 (de) * | 2002-11-30 | 2006-06-08 | Universität Potsdam | Verfahren zur Selektion von Zellen, die spezifisch bindende Moleküle produzieren |
WO2004078215A2 (en) | 2003-02-28 | 2004-09-16 | The Board Of Trustees Of The University Of Illinois | Use of antibody conjugated deoxycytidine kinase for adept |
CA2553261C (en) * | 2004-01-16 | 2014-03-18 | Stefan Barth | Immunokinases |
US20080044400A1 (en) * | 2004-12-09 | 2008-02-21 | Volker Schellenberger | Targeted enzyme prodrug therapy |
EP1800695A1 (en) * | 2005-12-21 | 2007-06-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Immuno-RNA-constructs |
CA2693155A1 (en) * | 2007-07-25 | 2009-01-29 | Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Self coupling recombinant antibody fusion proteins |
ES2572356T3 (es) | 2007-11-09 | 2016-05-31 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpos dirigidos contra VEGF y procedimientos |
WO2009143048A2 (en) | 2008-05-19 | 2009-11-26 | The Board Of Trustees Of The University Of Illinois | Use of specifically engineered enzymes to enhance the efficacy of prodrugs |
GB201308363D0 (en) * | 2013-05-09 | 2013-06-19 | Bagshawe Kenneth D | Tumour therapy |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4624846A (en) * | 1983-07-29 | 1986-11-25 | Immunomedics, Inc. | Method for enhancing target specificity of antibody localization and clearance of non-target diagnostic and therapeutic principles |
ATE81467T1 (de) * | 1987-02-24 | 1992-10-15 | Xoma Corp | Immunosuppression bei der auf immunotoxin basierten behandlung von menschen. |
GB8705477D0 (en) * | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
NZ225599A (en) * | 1987-08-04 | 1991-09-25 | Bristol Myers Co | Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells |
US4859449A (en) * | 1987-09-14 | 1989-08-22 | Center For Molecular Medicine And Immunology | Modified antibodies for enhanced hepatocyte clearance |
GB8809616D0 (en) * | 1988-04-22 | 1988-05-25 | Cancer Res Campaign Tech | Further improvements relating to drug delivery systems |
CA2055497A1 (en) * | 1989-03-13 | 1990-09-14 | Kenneth N. Matsumura | Method for reducing side effects of a drug |
WO1991009134A1 (en) * | 1989-12-15 | 1991-06-27 | Takeda Chemical Industries, Ltd. | Biospecific antibody to cancer cell and enzyme with prodrug-activating characteristics |
CA2062582C (en) * | 1991-03-27 | 1996-03-26 | Tse-Wen Chang | Methods and substances for recruiting therapeutic agents to solid tissues |
-
1992
- 1992-01-09 GB GB929200417A patent/GB9200417D0/en active Pending
-
1993
- 1993-01-11 JP JP51225193A patent/JP3592711B2/ja not_active Expired - Fee Related
- 1993-01-11 US US08/256,475 patent/US5658568A/en not_active Expired - Fee Related
- 1993-01-11 EP EP93901820A patent/EP0620741B1/en not_active Expired - Lifetime
- 1993-01-11 GB GB9410236A patent/GB2276623B/en not_active Revoked
- 1993-01-11 DE DE69326539T patent/DE69326539T2/de not_active Expired - Fee Related
- 1993-01-11 CA CA002124218A patent/CA2124218C/en not_active Expired - Lifetime
- 1993-01-11 ES ES93901820T patent/ES2139002T3/es not_active Expired - Lifetime
- 1993-01-11 WO PCT/GB1993/000039 patent/WO1993013805A1/en active IP Right Grant
-
1997
- 1997-06-30 US US08/885,281 patent/US6015556A/en not_active Expired - Fee Related
-
1999
- 1999-07-14 US US09/353,737 patent/US6299876B1/en not_active Expired - Fee Related
-
2003
- 2003-03-10 JP JP2003063997A patent/JP2003292458A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE69326539D1 (de) | 1999-10-28 |
GB2276623B (en) | 1995-10-18 |
GB9200417D0 (en) | 1992-02-26 |
US6299876B1 (en) | 2001-10-09 |
EP0620741A1 (en) | 1994-10-26 |
WO1993013805A1 (en) | 1993-07-22 |
US5658568A (en) | 1997-08-19 |
CA2124218A1 (en) | 1993-07-22 |
GB9410236D0 (en) | 1994-07-27 |
DE69326539T2 (de) | 2000-05-04 |
US6015556A (en) | 2000-01-18 |
JP3592711B2 (ja) | 2004-11-24 |
GB2276623A (en) | 1994-10-05 |
EP0620741B1 (en) | 1999-09-22 |
JP2003292458A (ja) | 2003-10-15 |
JPH07506338A (ja) | 1995-07-13 |
CA2124218C (en) | 2002-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2139002T3 (es) | Terapia medicamentosa citotoxica. | |
ES2159591T3 (es) | Composicion de liberacion controlada. | |
BR9407560A (pt) | Copolimeros elastômeros termoplásticos enxertados com silicone e composiçoes para tratamento dos cabelos e da pele contendo estes copolimeros | |
AR026165A1 (es) | Dispositivo para la administracion de drogas. | |
ES2031597T3 (es) | Aparato distribuidor con un miembro dispensador para entregar un agente beneficioso. | |
ES2105926B1 (es) | El uso de taxol para la fabricacion de una preparacion de infusion para el tratamiento del cancer. | |
ATE248597T1 (de) | Acyclovirhaltige antiherpesarzneistift zur topischen anwendung | |
ES2107203T3 (es) | Una formulacion de aerosol que contiene un adyuvante de dispersion derivado de un diol-diacido. | |
BR0014928A (pt) | Dispositivo e processo para distribuição de medicamento para um olho humano | |
HUP9904174A2 (hu) | Bőrön át történő adagoláshoz szánt gyógyszerkészítmények | |
GB2357969A (en) | Improvements in or relating to the treatment of lesions | |
SE8504945L (sv) | Farmaceutiska kompositioner innehallande antracyklinglykosider | |
ES2102921T3 (es) | Utilizacion de derivados de la hormona estimuladora de los melanocitos de tipo alfa para estimular el crecimiento de los cabellos. | |
ES2176421T3 (es) | Composicion topica gelificada estable que contiene un electrolito, un agente activo y etil hidroxietilcelulosa. | |
NO993385L (no) | Transdermalt terapeutisk system for avgivelse av hormoner | |
AR022404A1 (es) | Metodo y agentes para la terapia de radiacion mejorada | |
GB984464A (en) | Therapeutic compositions comprising bromelain | |
AR002743A1 (es) | Esmalte de unas, y la utilizacion de dicho esmalte para la preparacion de un medicamento para el tratamiento de onicomicosis. | |
IL164191A0 (en) | Stinging cells expressing an exogenous polynucleotide encoding a therapeutic, diagnostic or a cosme tic agent and methods compositions and devices utilizing such stinging cells or capsules derived therefrom for delivering the therapeutic, diagnostic or cosmetic agent into a tissue nanocyte inc. | |
ES2172558T3 (es) | Lubricante compatible con radiaciones para dispositivos medicos. | |
ECSP003685A (es) | Formulaciones orales de liberacion controlada | |
ES2106319T3 (es) | Uso de lactoferrina en la fabricacion de un medicamento para el tratamiento del reumatismo. | |
UY23355A1 (es) | Formulacion para verter destinada a la aplicacion de antihelminticos | |
ES2033181B1 (es) | Una tableta o capsula de herbicida para su aplicacion en arrozales. | |
CO5011042A1 (es) | Uso de una oxazolidinona para la fabricacion de un medicamento para administracion topica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 620741 Country of ref document: ES |